Novel Macrocyclic Compounds Targeting KRAS Mutations for Cancer Treatment
This patent provides novel macrocycle compounds that inhibit key mutants (G12D/G13D) of the KRAS oncogene, which is the most frequently mutated in human cancers. These compounds, along with their pharmaceutical compositions and protein complexes, are intended for the treatment of cancers driven by these mutations.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Lingxin Meng
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1021/acsmedchemlett.6c00032
- Primary Topic
- Protein Kinase Regulation and GTPase Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00